Apricus Biosciences IncFind Ratings Reports
APRICUS BIOSCIENCES INC's gross profit margin for the first quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. Sales have remained unchanged, but net income increased. APRICUS BIOSCIENCES INC has average liquidity. Currently, the Quick Ratio is 1.45 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 112.30% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY17||Q1 FY16|
|Net Sales ($mil)||0.0||0.0|
|Net Income ($mil)||8.07||-2.51|
|Balance Sheet||Q1 FY17||Q1 FY16|
|Cash & Equiv. ($mil)||3.76||7.09|
|Total Assets ($mil)||5.35||10.43|
|Total Debt ($mil)||0.0||8.75|
|Profitability||Q1 FY17||Q1 FY16|
|Gross Profit Margin||0.0||0.0|
|Return on Assets||58.75||-144.9|
|Return on Equity||-989.54||0.0|
|Debt||Q1 FY17||Q1 FY16|
|Share Data||Q1 FY17||Q1 FY16|
|Shares outstanding (mil)||7.74||6.18|
|Div / share||0.0||0.0|
|Book value / share||0.11||-1.11|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||426445.0||442129.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 13.80 indicates a significant premium versus the S&P 500 average of 3.02 and a discount versus the industry average of 15.08. The price-to-sales ratio is above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, APRICUS BIOSCIENCES INC proves to trade at a discount to investment alternatives within the industry.
|APRI NM||Peers 27.82||APRI NM||Peers 23.74|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
APRI's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
APRI's P/CF is negative making the measure meaningless.
|APRI 5.08||Peers 14.99||APRI NA||Peers 0.61|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
APRI's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|APRI 13.80||Peers 15.08||APRI 65.30||Peers 24.97|
Average. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
APRI is trading at a valuation on par with its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
APRI is expected to have an earnings growth rate that significantly exceeds its peers.
|APRI 2.26||Peers 9.39||APRI 17.71||Peers 8.35|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
APRI is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
APRI has a sales growth rate that significantly exceeds its peers.